Ritholtz Wealth Management Takes Position in Natera, Inc. $NTRA

Key Points

• Ritholtz Wealth Management acquired 1,754 shares of Natera, Inc. ($NTRA), valued at approximately $296,000, in the second quarter of the year.
• Natera's stock price increased by 3.8%, with the company reporting a revenue of $546.60 million for the last quarter, surpassing analysts' expectations.
• Insider trading activity includes significant share sales by directors, with one director selling 2,750 shares for $459,222.50, indicating potential shifts in insider sentiment.

Ritholtz Wealth Management acquired a new stake in Natera, Inc. (NASDAQ:NTRA - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 1,754 shares of the medical research company's stock, valued at approximately $296,000.

Several other institutional investors have also modified their holdings of NTRA. GAMMA Investing LLC lifted its stake in shares of Natera by 32.3% in the 1st quarter. GAMMA Investing LLC now owns 848 shares of the medical research company's stock valued at $120,000 after purchasing an additional 207 shares during the last quarter. ORG Partners LLC purchased a new stake in shares of Natera in the first quarter worth approximately $32,000. TrueMark Investments LLC purchased a new stake in shares of Natera in the first quarter worth approximately $854,000. Whalen Wealth Management Inc. purchased a new stake in shares of Natera in the first quarter worth approximately $289,000. Finally, HWG Holdings LP raised its holdings in shares of Natera by 0.4% in the first quarter. HWG Holdings LP now owns 40,907 shares of the medical research company's stock worth $5,785,000 after buying an additional 168 shares during the period. 99.90% of the stock is owned by institutional investors.

Natera Stock Up 3.8%

NTRA opened at $188.60 on Tuesday. The stock's fifty day moving average is $168.83 and its two-hundred day moving average is $158.98. The company has a market capitalization of $25.89 billion, a P/E ratio of -98.74 and a beta of 1.74. Natera, Inc. has a 52 week low of $117.27 and a 52 week high of $196.63.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The firm had revenue of $546.60 million for the quarter, compared to analysts' expectations of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The company's revenue for the quarter was up 32.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. Equities analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently weighed in on NTRA. Royal Bank Of Canada set a $268.00 price target on Natera and gave the stock an "outperform" rating in a report on Tuesday, September 2nd. Wells Fargo & Company began coverage on Natera in a report on Monday, September 22nd. They issued an "equal weight" rating and a $175.00 price target on the stock. Barclays reiterated an "overweight" rating and issued a $210.00 price target (up from $190.00) on shares of Natera in a report on Friday, August 8th. Canaccord Genuity Group reiterated a "buy" rating and issued a $200.00 price target on shares of Natera in a report on Tuesday, October 14th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $220.00 price target (up from $210.00) on shares of Natera in a report on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $196.81.

Insider Transactions at Natera

In other Natera news, Director Rowan E. Chapman sold 2,750 shares of the stock in a transaction on Thursday, August 28th. The stock was sold at an average price of $166.99, for a total transaction of $459,222.50. Following the sale, the director owned 6,015 shares of the company's stock, valued at approximately $1,004,444.85. This trade represents a 31.37% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Solomon Moshkevich sold 3,000 shares of the stock in a transaction on Friday, August 1st. The shares were sold at an average price of $132.89, for a total value of $398,670.00. Following the sale, the insider directly owned 123,059 shares in the company, valued at $16,353,310.51. This trade represents a 2.38% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 68,690 shares of company stock valued at $10,437,178. Company insiders own 5.63% of the company's stock.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.